halistanol trisulfate: structure given in first source; isolated from marine sponges [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 73361 |
| CHEMBL ID | 509296 |
| CHEBI ID | 80949 |
| MeSH ID | M0195798 |
| Synonym |
|---|
| halistanol trisulfate |
| ergostane-2,3,6-triol, 25-methyl-, tris(hydrogen sulfate), 2.beta.,3.alpha.,5.alpha.,6.alpha.)- |
| 103065-20-9 |
| halistanol sulfate |
| [(2s,3s,5s,6s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-2,3-disulfooxy-17-[(1r,4s)-1,4,5,5-tetramethylhexyl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-6-yl] hydrogen sulfate |
| 24,25-dimethylcholestane-2,3,6-triol, tris(hydrogen sulfate), (2.beta.,3.alpha.,6.alpha.) |
| [(2s,3s,5s,6s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-2,3-disulfooxy-17-[(2r,5s)-5,6,6-trimethylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-6-yl] hydrogen sulfate |
| C17159 |
| chebi:80949 , |
| CHEMBL509296 |
| ergostane-2,3,6-triol, 25-methyl-, tris(hydrogen sulfate), (2beta,3alpha,5alpha,6alpha,24zeta)- |
| 25-methylergostane-2,3,6-triyl tris(hydrogen sulfate) |
| Q27154920 |
| DTXSID60908179 |
| ergostane-2,3,6-triol, 25-methyl-, tris(hydrogen sulfate), (2.beta.,3.alpha.,5.alpha.,6.alpha.)- |
| Class | Description |
|---|---|
| ergostanoid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID354659 | Inhibition of recombinant ECE expressed in african green monkey COS cells assessed as endothelin formation by EIA assay | 1996 | Journal of natural products, Jun, Volume: 59, Issue:6 | Halistanol disulfate B, a novel sulfated sterol from the sponge Pachastrella sp.: inhibitor of endothelin converting enzyme. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.05) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||